EMERGENT BIOSOLUTIONS INC. Current Assets
EMERGENT BIOSOLUTIONS INC. (EBS) had Current Assets of $666.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $666.00M.
- 2026-03-31: Assets, Current $637.60M.
- 2025-12-31: Assets, Current $662.50M.
- 2025-09-30: Assets, Current $786.90M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $666.00M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $637.60M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $662.50M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $786.90M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $719.50M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $706.80M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $598.70M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $661.40M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $654.50M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $682.40M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $679.50M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $720.80M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $777.70M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.22B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $1.21B 10-K · filed 2024-03-08 | $1.21B 10-K · filed 2023-03-01 |
| 2022-09-30 | $1.10B 10-Q · filed 2023-12-11 | $1.12B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.08B 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $1.10B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $1.27B 10-K/A · filed 2023-12-11 | $1.27B 10-K · filed 2022-02-25 |
| 2021-09-30 | $1.11B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.16B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $1.18B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $1.20B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $958.80M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $795.90M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $626.60M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $686.20M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $700.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $692.70M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $528.50M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $620.80M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $563.15M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $541.31M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $476.65M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $485.40M 10-K · filed 2019-02-22 | $485.39M 10-K · filed 2018-02-23 |
| 2017-09-30 | $556.03M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $509.74M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $489.17M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $510.22M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $480.00M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $528.05M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $528.16M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $537.41M 10-K · filed 2017-02-28 | $538.61M 10-K · filed 2016-02-29 |
| 2015-09-30 | $473.49M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $435.49M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $405.81M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $432.18M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $383.63M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $345.45M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $327.20M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $273.12M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $234.01M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $248.16M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $237.08M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $263.35M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $252.94M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $243.22M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $239.54M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $254.42M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $236.76M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $223.84M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $243.49M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |